Ultimately, the results obtained from such approaches on the RyR family will pave the way to improve our understanding of allosteric long-range gating of channel opening and ligand binding effects, which are essential for drug development to treat RyR channelopathies. The gene discussed is RYR2; the disease is channelopathy.